| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10593480 | Bioorganic & Medicinal Chemistry Letters | 2012 | 6 Pages |
Abstract
A series of dual CCR3/H1 antagonists based on a bispiperidine scaffold were discovered. Introduction of an acidic group overcame hERG liability. Bioavailability was optimised by modulation of physico-chemical properties and physical form to deliver a compound suitable for clinical evaluation.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Ash Bahl, Patrick Barton, Keith Bowers, Steven Brough, Richard Evans, Christopher A. Luckhurst, Tobias Mochel, Matthew W.D. Perry, Aaron Rigby, Robert J. Riley, Hitesh Sanganee, Adam Sisson, Brian Springthorpe,